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OBJECTIVE
To explore prevalent metformin use as a potential moderator of the cardiovascular
effects of dipeptidyl peptidase 4 inhibitors (DPP-4i).
RESEARCH DESIGN AND METHODS
We performed a meta-analysis of the three major cardiovascular outcomes
trials examining DPP-4i. We used meta-regression to examine how the cardio-
vascular effects of DPP-4i differ between prevalent metformin users and baseline
nonusers.
RESULTS
While prevalentmetformin users experienced a trend toward improved cardiovascular
outcomeswith DPP-4i (summary hazard ratio [HR] 0.92 [95% CI 0.84, 1.01]), baseline
metformin nonusers showed a trend toward harm (HR 1.10 [95% CI 0.97, 1.26]). The
difference in overall DPP-4i effect between metformin user and nonuser subgroups
was statistically significant (P = 0.036).
CONCLUSIONS
Baseline metformin status may have a moderating effect on cardiovascular out-
comeswithDPP-4i use. This hypothesis-generating analysis suggests there is residual
uncertainty as to how DPP-4i affect cardiovascular outcomes, depending on concur-
rently prescribed medications.
Dipeptidyl peptidase 4 inhibitors (DPP-4i), which are often added to background met-
formin therapy as next-line agents for type 2 diabetes, appear to have a neutral effect
on cardiovascular outcomes relative to placebo (1–3). However, subgroup analyses of
recent cardiovascular outcomes trials (CVOTs) suggest that baseline metformin use
may serve as a moderator of the effectiveness of DPP-4i. Among prevalent metformin
users, each of the three major DPP-4i CVOTs reported a trend toward better cardio-
vascular outcomeswithDPP-4i; by contrast, each study reported a trend towardpoorer
outcomes with DPP-4i among baseline nonusers of metformin. Two of these studies
reported a significant or near-significant interaction between baseline metformin sta-
tus and DPP-4i status for the primary outcome (1,2). In order to further explore
prevalent metformin use as a potential moderator of the cardiovascular effects of
DPP-4i, we conducted a stratifiedmeta-analysis of the threemajor DPP-4i CVOTs (1–3).
RESEARCH DESIGN AND METHODS
This analysis focused on three recently published CVOTs examining agents in
the DPP-4i class (1–3). Each study’s supplementary appendix reported relevant
data for the subgroups of prevalent metformin users and baseline nonusers,
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including the number of patients in
each subgroup, a hazard ratio (HR) for
the primary composite study outcome
associated with DPP-4i use in each sub-
group, and a 95% CI for each subgroup
HR.
Because these studies had good con-
ceptual homogeneity in their design, pop-
ulations, interventions, and outcomes,
we performed quantitative synthesis
using a DerSimonian-Laird random-effects
model (4). As this analysis included only
three studies, we conservatively used the
Knapp-Hartung approach to adjust the SE
of the estimated coefficients (5). In meta-
analyses of #5 studies, the Knapp-
Hartung approach is associated with
acceptably low rates of type I error com-
pared with the DerSimonian-Laird ap-
proach, particularly when studies are
reasonably similar in size (as is the case
in this analysis) (6). We performed meta-
regression with metformin status as a
covariate to establish the statistical signif-
icance of the difference in overall DPP-4i
effect between prevalent metformin
users and baseline nonusers. Subgroup
summary HRs and 95% CIs were based
on estimates from this meta-regression
model. We evaluated statistical hetero-
geneity using CochranQ and I2 statistics.
All quantitative analyses were performed
using R (version 3.1.2), including R pack-
age “metafor” (version 1.9-7) for meta-
analysis.
RESULTS
This analysis included three large, multina-
tional trials, each of which randomized pa-
tients to receive a DPP-4i agent or placebo
in addition to their existing diabetes ther-
apy. Two studies exclusively included pa-
tients with known cardiovascular disease
(1,2), while the third included patients
with either established cardiovascular dis-
ease or multiple risk factors. Each study
examined a particular DPP-4i agent: sita-
gliptin (1), alogliptin (2), or saxagliptin (3).
The primary composite outcome for each
of these studies comprised cardiovascular
death, nonfatal myocardial infarction, or
nonfatal stroke, with one study addition-
ally including hospitalization for unstable
angina (1). Only primary composite out-
come data were presented by metformin
subgroup. Median follow-up duration
ranged from 1.5 to 3 years.
For the overall analytic population,
DPP-4i had a neutral summary effect on
the primary outcome (summary HR 0.99
[95% CI 0.87, 1.13]). However, prevalent
metformin users (Fig. 1) experienced a
trend toward reduction in the incidence
of the primary studyoutcomewithDPP-4i
(summary HR 0.92 [95% CI 0.84, 1.01]).
Individual study effects were consistent
(Cochran Q P = 0.37, I2 = 0.0%). By con-
trast, the baseline metformin nonusers
showed a trend toward harm with DPP-
4i (HR 1.10 [95% CI 0.97, 1.26]). Individual
study effects were again consistent (Co-
chran Q P = 0.75, I2 = 0.0%).
Usingmeta-regression, the difference in
overall DPP-4i effect between prevalent
metformin users and baseline nonusers
was statistically significant (P = 0.036),
indicating a difference in the relative
effects of DPP-4i based on metformin
status.
CONCLUSIONS
This stratified meta-analysis of three ma-
jor DPP-4i CVOTs shows that baseline
metformin status may be a moderator
of the effect of DPP-4i on cardiovascular
outcomes. Consistent with prior analyses
(7), DPP-4i use had a neutral effect on the
primary composite outcome in the overall
population; however, prevalent users of
metformin experienced a trend toward
reduction of cardiovascular events with
DPP-4i, while baseline nonusers showed a
trend toward harm. This difference in the
overall effect of DPP-4i betweenmetformin
user and nonuser subgroups was statisti-
cally significant, suggesting that the cardio-
vascular effects of DPP-4i agents may differ
depending on whether these medications
are coprescribed with metformin.
Because newer medication classes like
DPP-4i are typically added to background
metformin therapy (8), metformin’s im-
pact on the effectiveness of next-line
drugs is of great interest. Currently, how
diabetes medication classes interact to
Figure 1—Forest plot depicting the effect of DPP-4i on primary composite study outcomes, stratified bymetformin user/nonuser subgroups (P = 0.036 for
difference in DPP-4i effect between prevalent metformin users and baseline nonusers). N = number of patients.
affect cardiovascular outcomes is not well
understood. This hypothesis-generating
analysis suggests that there is residual un-
certainty as to whether DPP-4i are associ-
atedwith cardiovascular neutrality, benefit,
or even harm, depending on how these
medications are used in clinical practice.
Prevalent metformin users showed a
trend toward improved cardiovascular
outcomes with DPP-4i in this analysis.
One physiologic mechanism by which
metformin could potentiate the effec-
tiveness of DPP-4i is via glucagon-like
peptide 1 (GLP-1); metformin raises
GLP-1 levels (9,10), and DPP-4i act by
inhibiting GLP-1 degradation. It is there-
fore plausible that these drugs could in-
teract synergistically. Baseline nonusers
of metformin showed a trend toward
poorer outcomes with DPP-4i, raising
the possibility that off-target effects
may outweigh any benefits of DPP-4i
use in the absence of metformin.
While the effect of DPP-4i differed
significantly between prevalent metfor-
min users and baseline nonusers, met-
formin use is likely not the sole
difference between these subgroups.
For example, metformin use may be a
marker for baseline differences in rates
of chronic kidney disease or congestive
heart failure, for which this analysis
does not account. For this reason, it is
possible that metformin use itself does
not mediate the observed difference
inDPP-4i effect betweenmetformin users
and nonusers. Subsequent analyses
should incorporate statistical adjustment
for other population differences through
use of patient-level data and should seek
to assess available outcome measures in-
dividually rather than relying on compos-
ite outcomes.
We chose to focus exclusively on the
three major DPP-4i CVOTs because these
studies enrolled similar populations, used
similar primary outcomes, and all report-
eddata onmetformin subgroups. The low
heterogeneity on our stratified meta-
analyses attests to these studies’ similar-
ity. Of note, specific agents within the
DPP-4i class may interact with metformin
differently. Future research should fur-
ther examine metformin’s moderating
effects on individual DPP-4i agents and
also explore howmetforminmay interact
with other novel medication classes, such
as GLP-1 receptor agonists and sodium–
glucose cotransporter 2 inhibitors.
In summary, this hypothesis-generating
analysis suggests that baselinemetformin
status may have a moderating effect on
cardiovascular outcomeswith DPP-4i use.
These novel findings have great import
for clinical application of DPP-4i and sug-
gest intriguing areas for future investiga-
tion relating to DPP-4i and other diabetes
medication classes.
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